Stay updated on Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial
Sign up to get notified when there's something new on the Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial page.

Latest updates to the Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial page
- Check5 days agoChange DetectedA minor revision notice in the page footer shows an update from v3.3.3 to v3.3.4. There are no changes to study details, eligibility, or functionality.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedLocations are now organized under a single 'Locations' section with subheaders for California and Florida; the old 'California Locations' and 'Florida Locations' headings have been removed, and the page revision updated to v3.3.3.SummaryDifference0.3%

- Check56 days agoChange DetectedThe PubMed publications description was clarified to indicate auto-fill from PubMed. The revision tag was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check63 days agoChange DetectedRemoved a general government funding/operating status notice from the page, with no impact on the study's description, endpoints, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check77 days agoChange DetectedBoth screenshots show the same study record (NCT04491604) with identical core sections (title, brief summary, eligibility criteria, study design, and outcomes). Any observed differences appear to be cosmetic rather than content-related.SummaryDifference0.5%

- Check106 days agoChange DetectedMajor update: version bumped to v3.2.0 with an important government-operating-status notice and a new term (Epidermolysis bullosa dystrophica); old version v3.1.0 removed. If this page is disease-related, the new term may affect terminology or search indexing.SummaryDifference4%

Stay in the know with updates to Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial page.